The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
Cancers2021Vol. 13(8), pp. 1920–1920
Citations Over TimeTop 20% of 2021 papers
Abstract
Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin lymphoma limited to the central nervous system. It has a poor prognosis. Consensus has been reached on the treatment of newly diagnosed patients with high-dose methotrexate-based chemotherapy, but whether the addition of the monoclonal anti-CD20 antibody rituximab improves survival, as it does in systemic B-cell non-Hodgkin lymphoma, remains disputed. In this review, we reflect on the available evidence of the use of rituximab in PCNSL. Whether rituximab has any beneficial effect remains uncertain.
Related Papers
- → Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines(2005)91 cited
- CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.(2009)
- → Loss of CD20 expression in relapsed lymphomas after rituximab therapy(2003)58 cited
- → Immunophenotypic Changes and Clinical Outcome in B-Cell Lymphomas Treated with Rituximab(2006)39 cited
- → The incidence of anti-rituximab antibodies in patients with chronic lymphocytic leukemia(2020)1 cited